How Ozempic Maker Novo Nordisk Lost Its Shinenews2025-08-07T13:33:20+00:00August 7th, 2025|The New York Times|
Pill Causes Major Weight Loss in Eli Lilly Trial’s Resultsnews2025-08-07T11:37:14+00:00August 7th, 2025|The New York Times|
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drugnews2025-05-12T00:08:25+00:00May 12th, 2025|The New York Times|
WeightWatchers Files for Bankruptcy to Reduce $1 Billion in Debtnews2025-05-07T09:17:31+00:00May 7th, 2025|The New York Times|
What to Know About Eli Lilly’s Daily Pill for Weight Lossnews2025-04-17T21:24:51+00:00April 17th, 2025|The New York Times|
Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycatsnews2025-04-16T14:43:02+00:00April 16th, 2025|The New York Times|
Trump Rejects Proposal for Medicare to Cover Wegovy and Other Obesity Drugsnews2025-04-04T23:42:16+00:00April 4th, 2025|The New York Times|
How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?news2025-03-14T15:00:05+00:00March 14th, 2025|The New York Times|
Weight Loss Drug Will Be Offered for $499 a Month for Some Patientsnews2025-03-05T19:09:26+00:00March 5th, 2025|The New York Times|
Ladrones de Ozempic: la nueva ola delictiva en Brasilnews2025-02-15T10:10:09+00:00February 15th, 2025|The New York Times|
